Shares of Tectonic Therapeutic Inc. (NASDAQ:TECX) closed Jan. 30 at $54.84, up $29.12, or 113%, on what Leerink analyst David ...

Tectonic Therapeutic, Inc.'s stock surged 120% on positive Phase 1b data for TX45 in treating PH-HFpEF, offering a potential ...

Shares of Tectonic Therapeutic Inc. (NASDAQ:TECX) were trading at $55, up $29.28, or 113%, on positive interim data from the phase Ib acute hemodynamic trial of its lead product candidate, TX-45.

Tectonic Therapeutic shares doubled, to $56.80, after the company said it saw positive interim data from a Phase 1b acute hemodynamic clinical trial of its lead product candidate, TX45, a long-acting, ...

Tatsuya Yoshida, Mikito Takefuji, and Toyoaki Murohara in the Department of Cardiology, Nagoya University Graduate School of Medicine, identified an enzyme, alpha-kinase 2 (ALPK2) that is specifically ...

Tectonic Therapeutic on Thursday morning reported the successful result of its study testing TX45 in a left-sided heart ...

Per Sage Therapeutics, the BIIB offer significantly undervalues the company and is not in the best interest of shareholders. Biogen currently owns a 10.2% stake in SAGE, per a SEC filing by the ...

The trial's safety results were reassuring, with no serious adverse events or significant changes in vital signs, physical exams, or safety laboratory values post-administration of TX45. Transient ...

Tectonic Therapeutic (TECX) stock surges on positive interim data from Phase 1b trial for lead candidate TX45 in patients ...